✦ LIBER ✦

How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer

✍ Scribed by Kunitoh, H; Suzuki, K

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Trimodality Therapy for Locally Advanced

✍ Liriano, M.; Nichols, E.M.; Morris, C.G.; Burrows, W.; Battafarano, R.J.; Garofa 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Risk of Pneumonectomy After Induction Th

✍ Thomas A. d'Amato; Ahmad S. Ashrafi; Matthew J. Schuchert; Derar S.A. Alshehab; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 190 KB

The management of locally advanced non-s

✍ Sheehan, F; Goddard, K; Melosky, B; Evans, K; Murray, N 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 106 KB

Neoadjuvant and adjuvant therapy in the

✍ Michael T. Jaklitsch; Gary M. Strauss; David J. Sugarbaker 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 615 KB

Gemcitabine Plus Radiation Therapy in th

✍ David S. Ettinger 📂 Article 📅 2000 🏛 CIG Media Group, LP. 🌐 English ⚖ 122 KB

Neoadjuvant and adjuvant therapy in the

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 152 KB